Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06349642 2026-03-12

ELEPHAS-04

Recruiting

324 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Clear-cell metastatic renal cell carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06523634 2026-03-12

STEREOBED

Phase NA Recruiting

284 enrolled

Genitourinary

Prostatic Neoplasms

NCT06626022 2026-03-12

MUSIC-Screen

Phase 3 Recruiting

1,284 enrolled

Genitourinary

Prostate Cancer Screening

NCT07050771 2026-03-12

Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery

Phase 2 Recruiting

148 enrolled

GenitourinaryGynecologic

Urinary Bladder Neoplasms, Kidney Neoplasms, Neoplasms, Ovarian Neoplasms

NCT07460843 2026-03-12

Comparison of TB+PB and TB+6SB for Prostate Cancer Diagnosis

Phase NA Recruiting

592 enrolled

Genitourinary

Disease, Prostatic Neoplasms

NCT03424850 2026-03-11

Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy

Phase 1/2 Recruiting

36 enrolled

Genitourinary

Prostatic Neoplasms

NCT04987086 2026-03-11

68Ga-PSMA PET in the Renal Cell Carcinoma

Phase NA Recruiting

300 enrolled

Genitourinary

Kidney Neoplasms, Neoplasm Metastasis

NCT06040125 2026-03-11

Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial

Phase NA Recruiting

80 enrolled

Genitourinary

Prostatic Neoplasms

NCT06053658 2026-03-11

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

Phase 2 Recruiting

48 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT06437574 2026-03-11

Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer

Phase 2 Recruiting

140 enrolled

Genitourinary

Prostatic Neoplasms

NCT06488222 2026-03-11

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

Phase 2 Recruiting

34 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06542757 2026-03-11

Evaluation of Tumor Control Based on Serial Multiparametric MRI and Post-Treatment Biopsies For Patients Treated With Dose Intensification to the Dominant Intra-Prostatic Lesion (DIL) Using Ultra-Hypofractionated, MR-Guided Radiotherapy

Phase NA Recruiting

91 enrolled

Genitourinary

Prostatic Neoplasms

Clinical Trials

THUNDER

Skin Conductance for Predicting Spinal Anesthesia-Induced Hypotension in Geriatric Urologic Oncology Patients

PC-PEP

MetroWilms

Mechanisms of Resistance to PSMA Radioligand Therapy

Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

64Cu-GRIP B in Patients With Advanced Malignancies

TARGET-RCC

A Study of Tarlatamab for People With Prostate Cancer

Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer

OASIS

INSIGHT-PCa

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

Bladder Bank (a Prospective Banking Study)

EXACT

Oxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial

Prospective Clinical Study Comparing PROMS After Adaptive or Conventional Radiotherapy in Prostate Cancer

PRORAND

PSMA-VISION

Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer

Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)

99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer

Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

RATIONAL

A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

EMPOWER

A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer

An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Archival of Human Biological Samples in CU-Med Biobank

PNeoVCA

ELEPHAS-04

STEREOBED

MUSIC-Screen

Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery

Comparison of TB+PB and TB+6SB for Prostate Cancer Diagnosis

Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy

68Ga-PSMA PET in the Renal Cell Carcinoma

Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

Evaluation of Tumor Control Based on Serial Multiparametric MRI and Post-Treatment Biopsies For Patients Treated With Dose Intensification to the Dominant Intra-Prostatic Lesion (DIL) Using Ultra-Hypofractionated, MR-Guided Radiotherapy